Clovis Oncology Appoints Two New Directors to its Board

BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS), announced today the appointment of
Robert W. Azelby and Richard A. Fair to the company’s Board of Directors.

“Clovis will be well served by the addition of these two individuals to
our Board, given their deep experience in managing pipeline
diversification, launch and commercialization for innovative oncology
therapeutics at leading global biotech companies,” said Patrick J.
Mahaffy, President and CEO of Clovis Oncology. “Robert is a respected
healthcare executive who brings a breadth of experience related to the
commercialization of products in new and expanded oncology indications.
Rick brings to the Board a distinguished track record having led the
growth and expansion of a leading biopharmaceutical company and now
leading an oncology-focused organization.”

Robert W. Azelby has served as the President and Chief Executive
Officer, and a member of the board of directors, of Alder
BioPharmaceuticals, Inc. since June 2018. From November 2015 to May
2018, Mr. Azelby served as executive vice president, chief commercial
officer of Juno Therapeutics, Inc. From June 2012 to October 2015,
Mr. Azelby served as vice president and general manager, oncology at
Amgen Inc. From October 2010 to May 2012, he served as Amgen’s vice
president, Amgen Oncology Sales. Prior to that, he served in various
positions at Amgen, including periods as vice president, commercial
effectiveness unit and general manager of Amgen Netherlands. Mr. Azelby
previously served on the board of directors of Cascadian Therapeutics,
Inc. Mr. Azelby holds a B.A. in Economics and Religious Studies from the
University of Virginia and an M.B.A. from Harvard Business School. The
Company believes Mr. Azelby possesses specific attributes that qualify
him to serve as a member of the Company’s board of directors, including
his years of leadership and commercial experience in the oncology
industry.

Richard A. Fair has served as President and Chief Executive Officer, and
a member of the board of directors, of Bellicum Pharmaceuticals, Inc.
since January 2017. Prior to joining Bellicum, Mr. Fair served as Senior
Vice President, Therapeutic Head Oncology Global Product Strategy at
Genentech, Inc., a subsidiary of Roche Holding AG. From April 2006 to
January 2014, Mr. Fair held other positions at Genentech, including Vice
President, Global Product Strategy Hematology & Signaling, from November
2012 through December 2013, and Vice President, Sales & Marketing, Oral
Oncolytics, from May 2010 to November 2012. Prior to Genentech, Mr. Fair
held positions at Johnson & Johnson, a pharmaceutical and medical device
company. Mr. Fair received his B.S. in computer science from the
University of Michigan and his MBA from Columbia University. The Company
believes Mr. Fair possesses specific attributes that qualify him to
serve as a member of the Company’s board of directors, including his
years of leadership and commercial experience in the oncology industry.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of
cancer populations, and simultaneously develops, with partners,
diagnostic tools that direct a compound in development to the population
that is most likely to benefit from its use. Clovis Oncology is
headquartered in Boulder, Colorado, and has additional offices in San
Francisco and Oakland, California and Cambridge, UK. Please visit www.clovisoncology.com for
more information.

Clovis Oncology Forward-looking Statement

To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from that expressed
or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in our
clinical development programs for our drug candidates and those of our
partners, the initiation, enrollment, timing and results of our planned
clinical trials, and the risk that final results of trials may differ
from initial or interim results. Clovis Oncology does not undertake to
update or revise any forward-looking statements. A further description
of risks and uncertainties can be found in Clovis Oncology’s filings
with the Securities and Exchange Commission, including its Annual Report
on Form 10-K and its reports on Form 10-Q and Form 8-K

Contacts

Clovis Oncology
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
or
Breanna
Burkart, 303-625-5023
bburkart@clovisoncology.com

Leave a Reply

Sky Optics Media drone video